Abstract
Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEPO) to manage anemia in PEG-IFN/RBV treated patients, with the objective of maintaining the RBV dose, but currently no official guidelines exist. Actually, rHuEPO exact utilizable dose in PEG-IFN/RBV treated patients is not known. We describe the case of a patient with severe ribavirin-induced anemia.
MeSH terms
-
Alanine Transaminase / blood
-
Anemia / drug therapy*
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / therapeutic use
-
Aspartate Aminotransferases / blood
-
Erythropoietin / administration & dosage*
-
Female
-
Hematocrit
-
Hemoglobins / analysis
-
Hepatitis C / drug therapy
-
Humans
-
Middle Aged
-
Recombinant Proteins
-
Ribavirin / adverse effects*
-
Ribavirin / therapeutic use
Substances
-
Antiviral Agents
-
Hemoglobins
-
Recombinant Proteins
-
epoetin beta
-
Erythropoietin
-
Ribavirin
-
Aspartate Aminotransferases
-
Alanine Transaminase